AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8703705 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral furosemide
Number of subjects: 120
Study 8703705 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 120
Study 2057975 — intervention group
Group type: EXPERIMENTAL
Intervention: Headache in patients with acute cerebral or retinal ischemia
Number of subjects: 3126
Study 2057975 — intervention group
Group type: EXPERIMENTAL
Intervention: Headache presence
Number of subjects: 3126
Study 2057975 — intervention group
Group type: EXPERIMENTAL
Intervention: Headache in patients with monocular visual symptoms
Number of subjects: 3126
Study 2057975 — intervention group
Group type: EXPERIMENTAL
Intervention: Headache occurrence related to infarct type
Number of subjects: 3126
Study 2057975 — intervention group
Group type: EXPERIMENTAL
Intervention: Headache and heart disease
Number of subjects: 3126
Study 2057975 — intervention group
Group type: EXPERIMENTAL
Intervention: Headache and ischemic symptoms
Number of subjects: 3126
Study 6536520 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene catheters
Number of subjects: 52
Study 6536520 — intervention group
Group type: COMPARATOR
Intervention: Silicone catheters
Number of subjects: 52
Study 6536520 — intervention group
Group type: COMPARATOR
Intervention: Polyurethane catheters
Number of subjects: 52
Study 31274739 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical stimulation of the cornea
Number of subjects: 15
Study 31274739 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical stimulation of the cornea
Number of subjects: 15
Study 31274739 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal stimulation (mechanical and chemical)
Number of subjects: 15
Study 29558490 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration training with maslinic acid (WBVT/MA)
Number of subjects: 26
Study 29558490 — intervention group
Group type: COMPARATOR
Intervention: Whole-body vibration training with placebo (WBVT/P)
Number of subjects: 26
Study 26856618 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dydrogesterone (20mg daily)
Number of subjects: 48
Study 26856618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 24708224 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey isolate (WI)
Number of subjects: 0
Study 24708224 — intervention group
Group type: COMPARATOR
Intervention: Gluten (GLU)
Number of subjects: 0
Study 24708224 — intervention group
Group type: COMPARATOR
Intervention: Cod (COD)
Number of subjects: 0
Study 24708224 — intervention group
Group type: COMPARATOR
Intervention: Casein
Number of subjects: 0
Study 23006411 — intervention group
Group type: COMPARATOR
Intervention: Combination exercise training
Number of subjects: 64
Study 23006411 — intervention group
Group type: COMPARATOR
Intervention: Resistance exercise training
Number of subjects: 64
Study 20298820 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial body weight-supported treadmill training (PBWSTT) for 9 weeks, twice weekly.
Number of subjects: 34
Study 20298820 — intervention group
Group type: COMPARATOR
Intervention: Overground walking practice for 9 weeks, twice weekly.
Number of subjects: 34
Study 17381930 — intervention group
Group type: EXPERIMENTAL
Intervention: Price discounts
Number of subjects: 97
Study 17381930 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education
Number of subjects: 97
Study 17381930 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of price discounts and nutrition education
Number of subjects: 97
Study 17381930 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 97
Study 17390928 — intervention group
Group type: EXPERIMENTAL
Intervention: Cath‐Assist device; designed to facilitate female urethral catheterization by exposing the vulvar vestibule, isolating the urethral opening, and blocking the entrance to the vagina.
Number of subjects: 1
Study 15118483 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 41
Study 15118483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 11731813 — intervention group
Group type: EXPERIMENTAL
Intervention: 17D yellow fever vaccine administered at 6 months
Number of subjects: 420
Study 11731813 — intervention group
Group type: EXPERIMENTAL
Intervention: 17D yellow fever vaccine administered at 9 months
Number of subjects: 420
Study 11731813 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 420
Study 9248050 — intervention group
Group type: EXPERIMENTAL
Intervention: Actors' self-presentation influenced by another person's self-description; observed positivity matched the other's positivity.
Number of subjects: 0
Study 9248050 — intervention group
Group type: EXPERIMENTAL
Intervention: Actors' metaperceptions connected to their general beliefs about themselves.
Number of subjects: 0
Study 9248050 — intervention group
Group type: EXPERIMENTAL
Intervention: Blindness effect driven primarily by actors low in self-esteem.
Number of subjects: 0
Study 8518900 — intervention group
Group type: EXPERIMENTAL
Intervention: One-layer anastomosis
Number of subjects: 107
Study 8518900 — intervention group
Group type: COMPARATOR
Intervention: Two-layer anastomosis
Number of subjects: 107
Study 3327637 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic systemic antibiotics
Number of subjects: 71
Study 3327637 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antibiotic prophylaxis)
Number of subjects: 71
Study 31283053 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (64 IU)
Number of subjects: 52
Study 31283053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 28185672 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine (mean daily dose 4.2 mg)
Number of subjects: 461
Study 28185672 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (mean daily dose 3.8 mg)
Number of subjects: 461
Study 26466996 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial artery (RA) grafts
Number of subjects: 200
Study 26466996 — intervention group
Group type: COMPARATOR
Intervention: Saphenous vein graft (SVG)
Number of subjects: 200
Study 23788362 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0
Study 23788362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21319157 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 3013
Study 21319157 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 3013
Study 19670818 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitaprost plus
Number of subjects: 0
Study 17928726 — intervention group
Group type: EXPERIMENTAL
Intervention: IgY‐GP gel subgingivally applied with subgingival scaling and root planing
Number of subjects: 10
Study 17928726 — intervention group
Group type: COMPARATOR
Intervention: Subgingival scaling and root planing alone (Control)
Number of subjects: 10
Study 17928726 — intervention group
Group type: EXPERIMENTAL
Intervention: IgY‐GP gel
Number of subjects: 10
Study 15764039 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA/UVB phototherapy (Group I)
Number of subjects: 31
Study 15764039 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA/UVB + topical corticosteroids (Group II)
Number of subjects: 31
Study 12014489 — intervention group
Group type: EXPERIMENTAL
Intervention: Coloured overlays
Number of subjects: 233
Study 9696226 — intervention group
Group type: EXPERIMENTAL
Intervention: Sperm motility parameters (assessed with computer‐aided sperm analysis)
Number of subjects: 150
Study 9696226 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent normal morphology (determined with strict criteria)
Number of subjects: 150
Study 9696226 — intervention group
Group type: EXPERIMENTAL
Intervention: Samples achieving > or =50% fertilization
Number of subjects: 150
Study 9696226 — intervention group
Group type: EXPERIMENTAL
Intervention: Samples achieving pregnancy
Number of subjects: 150
Study 7805972 — intervention group
Group type: COMPARATOR
Intervention: Ritodrine tablets
Number of subjects: 32
Study 7805972 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release capsules
Number of subjects: 32
Study 2683423 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL-rich serum fractions (HDLF)
Number of subjects: 35
Study 31217069 — intervention group
Group type: EXPERIMENTAL
Intervention: BRiMS intervention (13-week education and exercise programme) plus usual care
Number of subjects: 56
Study 31217069 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 56
Study 28571563 — intervention group
Group type: EXPERIMENTAL
Intervention: MFFP intervention
Number of subjects: 0
Study 28571563 — intervention group
Group type: COMPARATOR
Intervention: Advice
Number of subjects: 0
Study 28571563 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 0
Study 25380107 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% or 23.4% hypertonic saline (HTS) as bolus therapy
Number of subjects: 25
Study 25380107 — intervention group
Group type: COMPARATOR
Intervention: 20% mannitol
Number of subjects: 25
Study 23511556 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentivirus-mediated AIB1 knockdown
Number of subjects: 146
Study 23511556 — intervention group
Group type: EXPERIMENTAL
Intervention: AIB1 overexpression
Number of subjects: 146
Study 21618480 — intervention group
Group type: EXPERIMENTAL
Intervention: Avotermin 500 ng per 100 µl per linear cm of wound margin, administered by intradermal injection to the groin and distal wound margins of one leg.
Number of subjects: 156
Study 21618480 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered to the other leg.
Number of subjects: 156
Study 19081393 — intervention group
Group type: EXPERIMENTAL
Intervention: Barber-based intervention (BP check with each haircut and encouragement for medical referral)
Number of subjects: 0
Study 19081393 — intervention group
Group type: COMPARATOR
Intervention: No active intervention (control group)
Number of subjects: 0
Study 16401443 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term Tai Chi training (1 to 3 years)
Number of subjects: 48
Study 16401443 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term Tai Chi training (3 months)
Number of subjects: 48
Study 16401443 — intervention group
Group type: COMPARATOR
Intervention: No Tai Chi training (nonpractitioners)
Number of subjects: 48
Study 15865549 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (4 g/0.5 g q8h)
Number of subjects: 314
Study 15865549 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin/sulbactam (2 g/1 g q6h)
Number of subjects: 314
Study 15865549 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam
Number of subjects: 314
Study 15865549 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin/sulbactam
Number of subjects: 314
Study 15865549 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam and Ampicillin/sulbactam
Number of subjects: 314
Study 11206417 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (1 mU/kg/min)
Number of subjects: 9
Study 11206417 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (2 mU/kg/min)
Number of subjects: 9
Study 11206417 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycaemia (5.6 mmol/l, 11.1 mmol/l, 16.7 mmol/l)
Number of subjects: 9
Study 11206417 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin + Hyperglycaemia with somatostatin
Number of subjects: 9
Study 11206417 — intervention group
Group type: COMPARATOR
Intervention: Basal conditions (no somatostatin)
Number of subjects: 9
Study 9205656 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva Orthana (mucin-containing oral spray)
Number of subjects: 35
Study 9205656 — intervention group
Group type: COMPARATOR
Intervention: Placebo (mucin-free spray)
Number of subjects: 35
Study 8440931 — intervention group
Group type: EXPERIMENTAL
Intervention: D protein vaccine (500 micrograms)
Number of subjects: 0
Study 8440931 — intervention group
Group type: COMPARATOR
Intervention: D protein vaccine
Number of subjects: 0
Study 3619219 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 30
Study 3619219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30907203 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallbladder stone disease cohort
Number of subjects: 9362
Study 30907203 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallbladder stone disease men with cholecystectomy
Number of subjects: 9362
Study 28350401 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide (LPS) pre-treatment
Number of subjects: 8
Study 28350401 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) pre-treatment
Number of subjects: 8
Study 26143536 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin treatment
Number of subjects: 0
Study 26143536 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 22767151 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg of TER
Number of subjects: 7
Study 22767151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 21148518 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment with sulphadoxine-pyrimethamine (SP)
Number of subjects: 270
Study 21148518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study 21148518 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive women
Number of subjects: 270
Study 18650629 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia-based information program (MM-IP)
Number of subjects: 80
Study 18650629 — intervention group
Group type: COMPARATOR
Intervention: Standard informed consent process
Number of subjects: 80
Study 17050202 — intervention group
Group type: EXPERIMENTAL
Intervention: nested-PCR assay
Number of subjects: 72
Study 17050202 — intervention group
Group type: EXPERIMENTAL
Intervention: RQ-PCR analysis
Number of subjects: 72
Study 17050202 — intervention group
Group type: EXPERIMENTAL
Intervention: antigenemia assay
Number of subjects: 72
Study 17050202 — intervention group
Group type: COMPARATOR
Intervention: antithymocyte globulin conditioning
Number of subjects: 72
Study 15344541 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (LPZ) 30 mg/day
Number of subjects: 0
Study 15344541 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (LPZ) 15 mg/day
Number of subjects: 0
Study 15344541 — intervention group
Group type: COMPARATOR
Intervention: Famotidine (FAM) 40 mg/day
Number of subjects: 0
Study 11002217 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion (HAI) with 5‐FU at 600 mg/m(2)/day for 2 consecutive days per week and oral UFT at 400 mg/day for 5‐7 days per week, repeated 10 times (Group A)
Number of subjects: 58
Study 11002217 — intervention group
Group type: COMPARATOR
Intervention: Oral UFT at 400 mg/day for 6 months (Group B)
Number of subjects: 58
Study 9021437 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release theophylline (SR-T)
Number of subjects: 21
Study 9021437 — intervention group
Group type: COMPARATOR
Intervention: Oral fenoterol 2.5 mg 3 times daily
Number of subjects: 21
Study 7940144 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.25% eyedrops (during treatment)
Number of subjects: 26
Study 7940144 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol withdrawn (off treatment)
Number of subjects: 26
Study 7940144 — intervention group
Group type: COMPARATOR
Intervention: Ocular normotensive control
Number of subjects: 26
Study 7940144 — intervention group
Group type: COMPARATOR
Intervention: Ocular hypertensives
Number of subjects: 26
Study 7940144 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all groups)
Number of subjects: 26
Study 3064818 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh human milk or fortified human milk with protein intake of 2.1 to 3.3 g/kg/day
Number of subjects: 33
Study 3064818 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein intake on the 21st day of life
Number of subjects: 33
Study 31600531 — intervention group
Group type: EXPERIMENTAL
Intervention: Large BCCs
Number of subjects: 248
Study 31600531 — intervention group
Group type: COMPARATOR
Intervention: Mohs micrographic surgery
Number of subjects: 248
Study 31246714 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Extension (SE)
Number of subjects: 9
Study 31246714 — intervention group
Group type: COMPARATOR
Intervention: Sleep Restriction (SR)
Number of subjects: 9
Study 31246714 — intervention group
Group type: COMPARATOR
Intervention: Normal Sleep (NS)
Number of subjects: 9
Study 28323846 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (self-management program)
Number of subjects: 47
Study 26232904 — intervention group
Group type: EXPERIMENTAL
Intervention: Encouragement message
Number of subjects: 6021
Study 26232904 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored message about low-cost vaccination
Number of subjects: 6021
Study 26232904 — intervention group
Group type: COMPARATOR
Intervention: General education
Number of subjects: 6021
Study 26232904 — intervention group
Group type: COMPARATOR
Intervention: Education tailored to reason for non-vaccination
Number of subjects: 6021
Study 24617235 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture bloodletting combined with penicillin
Number of subjects: 150
Study 24617235 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture bloodletting
Number of subjects: 150
Study 24617235 — intervention group
Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 150
Study 20840874 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder about the txt2stop trial plus a message that there were only 300 places left
Number of subjects: 1862
Study 20840874 — intervention group
Group type: COMPARATOR
Intervention: Reminder about the trial only
Number of subjects: 1862
Study 18318773 — intervention group
Group type: EXPERIMENTAL
Intervention: Udenafil 25 mg
Number of subjects: 40
Study 18318773 — intervention group
Group type: EXPERIMENTAL
Intervention: Udenafil 50 mg
Number of subjects: 40
Study 18318773 — intervention group
Group type: EXPERIMENTAL
Intervention: Udenafil 100 mg
Number of subjects: 40
Study 18318773 — intervention group
Group type: EXPERIMENTAL
Intervention: Udenafil 200 mg
Number of subjects: 40
Study 18318773 — intervention group
Group type: EXPERIMENTAL
Intervention: Udenafil 300 mg
Number of subjects: 40
Study 18318773 — intervention group
Group type: EXPERIMENTAL
Intervention: Udenafil 100 mg (multiple dose)
Number of subjects: 40
Study 18318773 — intervention group
Group type: EXPERIMENTAL
Intervention: Udenafil 200 mg (multiple dose)
Number of subjects: 40
Study 18318773 — intervention group
Group type: COMPARATOR
Intervention: Placebo (single dose)
Number of subjects: 40
Study 18318773 — intervention group
Group type: COMPARATOR
Intervention: Placebo (multiple dose)
Number of subjects: 40
Study 16927920 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic pressure variations (SPV) > 12 mmHg
Number of subjects: 50
Study 16927920 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta down > 5 mmHg
Number of subjects: 50
Study 16927920 — intervention group
Group type: EXPERIMENTAL
Intervention: SPV ≤ 12 mmHg
Number of subjects: 50
Study 16927920 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta down = 5 mmHg
Number of subjects: 50
Study 16927920 — intervention group
Group type: COMPARATOR
Intervention: Classic pressure parameters (MAP, CVP, PCWP)
Number of subjects: 50
Study 12830439 — intervention group
Group type: EXPERIMENTAL
Intervention: Short daily hemodialysis (HD)
Number of subjects: 0
Study 12830439 — intervention group
Group type: EXPERIMENTAL
Intervention: Long nocturnal hemodialysis (HD)
Number of subjects: 0
Study 12830439 — intervention group
Group type: COMPARATOR
Intervention: Conventional thrice-weekly hemodialysis (HD)
Number of subjects: 0
Study 14639559 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training with a leg cycle ergometer for 8 weeks
Number of subjects: 92
Study 14639559 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 92
Study 11172996 — intervention group
Group type: EXPERIMENTAL
Intervention: Fastrach group (endotracheal tube alone)
Number of subjects: 172
Study 11172996 — intervention group
Group type: COMPARATOR
Intervention: Fastrach/Trachlight group (endotracheal tube with Trachlight)
Number of subjects: 172
Study 11172996 — intervention group
Group type: EXPERIMENTAL
Intervention: Fastrach group
Number of subjects: 172
Study 11172996 — intervention group
Group type: COMPARATOR
Intervention: Fastrach group and Fastrach/Trachlight group
Number of subjects: 172
Study 8887197 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone-releasing factor (GRF), 1,000 mg/day, given in addition to follicle-stimulating hormone (FSH)
Number of subjects: 42
Study 8887197 — intervention group
Group type: COMPARATOR
Intervention: Follicle-stimulating hormone (FSH) alone (control group)
Number of subjects: 42
Study 8887197 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone-releasing factor (GRF) with FSH
Number of subjects: 42
Study 1355943 — intervention group
Group type: EXPERIMENTAL
Intervention: Carnitine and cobamamide
Number of subjects: 0
Study 1355943 — intervention group
Group type: COMPARATOR
Intervention: Standard nonspecific treatment
Number of subjects: 0
Study 1355943 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of carnitine and cobamamide
Number of subjects: 0
Study 6148163 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid stimulating antibody (TSAb) determinations before and at the end of treatment
Number of subjects: 55
Study 6148163 — intervention group
Group type: EXPERIMENTAL
Intervention: End-treatment TSAb levels greater than 350%
Number of subjects: 55
Study 6148163 — intervention group
Group type: EXPERIMENTAL
Intervention: End-treatment TSAb levels less than 350% or negative
Number of subjects: 55
Study 6148163 — intervention group
Group type: EXPERIMENTAL
Intervention: TSAb determined during follow-up
Number of subjects: 55
Study 3789694 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (3 X 10(6) IU of alpha 2b interferon, administered by subcutaneous injection, three times weekly for 12 weeks)
Number of subjects: 37
Study 3789694 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered by subcutaneous injection, three times weekly for 12 weeks)
Number of subjects: 37
Study 31615456 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive smartphone application (APP) for weight, diet, and physical activity tracking, including educational videos and real-time interaction with health professionals.
Number of subjects: 200